Strigas J, Burcher E
School of Physiology and Pharmacology, University of New South Wales, Sydney, Australia.
Eur J Pharmacol. 1996 Sep 12;311(2-3):177-86. doi: 10.1016/0014-2999(96)00412-8.
The distribution of tachykinin receptors in guinea-pig airways was studied using newly developed selective radioligands, [125I][Lys5,Tyr(I2)7,MeLeu9,Nle10]neurokinin A-(4-10) for NK2 receptors and [125I]Bolton-Hunter-[Sar9,Met(O2)11]substance P for NK1 receptors. Optimum incubation times were 60 and 45 min for tachykinin NK2 and NK1 sites, respectively, in slide-mounted sections of guinea-pig lung. Bacitracin (40 micrograms/ml) greatly reduced specific binding of [125I][Lys5,Tyr(I2)7,MeLeu9,Nle10]neurokinin A-(4-10), whereas phosphoramidon (1 and 10 microM) and bacitracin (40 micrograms/ml) significantly increased the specific binding of [125I]Bolton-Hunter-[Sar9,Met(O2)11]substance P. Dense specific binding of [125I]Bolton-Hunter-[Sar9,Met(O2)11]substance P occurred over bronchial smooth muscle of large and small airways, with moderate binding on bronchial epithelium and over pulmonary arterial smooth muscle. Moderate specific binding of [125I][Lys5,Tyr(I2)7, MeLeu9,Nle10]neurokinin A-(4-10) was associated with bronchial smooth muscle of mainly large airways but not with other histological regions. This is the first autoradiographic report of (a low density of) tachykinin NK2 binding sites on airway smooth muscle and supports the potent actions of NK2 receptor ligands as contractile agents in guinea-pig isolated bronchi.
使用新开发的选择性放射性配体,即用于NK2受体的[125I][Lys5,Tyr(I2)7,MeLeu9,Nle10]神经激肽A-(4 - 10)和用于NK1受体的[125I]博尔顿-亨特-[Sar9,Met(O2)11]P物质,研究了豚鼠气道中速激肽受体的分布。在豚鼠肺的载玻片切片中,速激肽NK2和NK1位点的最佳孵育时间分别为60分钟和45分钟。杆菌肽(40微克/毫升)大大降低了[125I][Lys5,Tyr(I2)7,MeLeu9,Nle10]神经激肽A-(4 - 10)的特异性结合,而磷酰胺脒(1和10微摩尔)和杆菌肽(40微克/毫升)显著增加了[125I]博尔顿-亨特-[Sar9,Met(O2)11]P物质的特异性结合。[125I]博尔顿-亨特-[Sar9,Met(O2)11]P物质在大小气道的支气管平滑肌上有密集的特异性结合,在支气管上皮和肺动脉平滑肌上有中等结合。[125I][Lys5,Tyr(I2)7,MeLeu9,Nle10]神经激肽A-(4 - 10)的中等特异性结合主要与大气道的支气管平滑肌相关,而与其他组织学区域无关。这是关于气道平滑肌上速激肽NK2结合位点(低密度)的首次放射自显影报告,并支持NK2受体配体作为豚鼠离体支气管收缩剂的强效作用。